October 28th 2024
Maha Hussain, MD, FACP, FASCO, spoke about BRCA testing and ctDNA as diagnostic tools and PSMA-imaging and -targeted approaches in prostate cancer.
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
European Commission Approves 177Lu Vipivotide Tetraxetan Plus ADT for Prostate Cancer Subset
December 17th 2022177Lu vipivotide tetraxetan becomes first targeted radioligand treatment approved by the European Commission for prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.
Follow-Up Data Show Tazemetostat Remains Safe, Elicits Benefit in Patients With Prostate Cancer
December 2nd 2022At a median follow-up of 17.4 months, half of the enrolled patients with metastatic castration-resistant prostate cancer experienced a decrease in PSA level from baseline following treatment with tazemetostat in combination with abiraterone acetate or enzalutamide.
Novel PSMA-TRT-based Triplet Regimen Appears Effective in Prostate Cancer
December 2nd 2022All patients with chemo-naïve metastatic castration-resistant prostate cancer experienced PSA decline, and half the cohort experienced a PSA decline greater than 50% after treatment with a novel PSMA-targeted radionuclide therapy.
PSMA Remains ‘Relevant’ But Needs to Be ‘Improved Upon’ for Treating Prostate Cancer
December 1st 2022“With more potent agents, can we actually cure patients [with prostate cancer]? I'm not so sure about that…because of heterogeneity,” said an expert from NewYork-Presbyterian – Weill Cornell Medical Center in New York City. “So we'll see. But I think with combinations, maybe someday we're going to be able to get there.”
Neeraj Agarwal, MD, Discusses Potential Link Between ctDNA, AR Aberrations, and Survival in mCSPC
November 26th 2022The appearance of circulating tumor DNA and androgen receptor aberrations yielded lower overall survival rates for patients with metastatic castration-sensitive prostate cancer during the phase 3 TITAN trial, according to Agarwal, MD.
PSMA-PET SUVmean Predictive of Favorable Response to 177Lu-PSMA-617 Than Cabazitaxel in mCRPC
November 10th 2022According to findings from a biomarker analysis of the phase 2 TheraP trial, mean standardized uptake value of PSMA-PET predicted favorable responses to 177Lu-PSMA-617 compared with cabazitaxel in patients with metastatic castration-resistant prostate cancer.
Darolutamide Plus ADT and Docetaxel Improves Quality of Life Vs Placebo in mHSPC
October 31st 2022Quality of life data from the phase 3 ARASENS study highlighted how early treatment intensification with darolutamide plus standard androgen deprivation therapy and docetaxel improved patient-relevant end points compared with placebo in the management of metastatic hormone-sensitive prostate cancer.
Post-Operative iSRT Plus Degarelix Yields Improved MFS in Prostate Cancer With Elevated PSA
October 28th 2022Patients with prostate cancer who experienced an increase in prostate-specific antigen level after radical prostatectomy appeared to benefit from a short course of androgen deprivation therapy after post-operative immediate salvage radiotherapy.
High Detection Rates Achieved With 18F-rhPSMA-7.3 PET in Recurrent Prostate Cancer
October 26th 2022Data from the phase 3 SPOTLIGHT trial indicated that 18F-rhPSMA-7.3 PET yielded a positive detection rate in patients with recurrent prostate cancer, and increased along with prostate-specific antigen level.
Conventional Radiotherapy and 5 Fraction SBRT Produce Comparable Toxicity in Prostate Cancer
October 24th 2022According to findings from the phase 3 PACE-B trial, genitourinary and gastrointestinal toxicities were similar among patients with prostate cancer receiving conventionally fractioned or moderately hypofractionated radiotherapy and stereotactic body radiotherapy.
Phase 3 TRITON3 Trial Meets Primary End Point of Radiographic PFS With Rucaparib for mCRPC
October 3rd 2022Results from the phase 3 TRITON3 trial demonstrated that radiographic progression-free survival was significantly improved when patients with metastatic castration-resistant prostate cancer were treated with rucaparib monotherapy vs physician’s choice.
PSA Levels at 8 Months Predict Survival Outcomes With ADT Combinations in mCRPC
October 3rd 2022A recent analysis of data from the phase 3 PEACE-1 study reveals a correlation between 8-month prostate-specific antigen levels and survival outcomes in patients with metastatic castration-sensitive prostate cancer who are treated with systemic therapy regimens that include androgen deprivation therapy.
Despite Improving Responses, Pembrolizumab/Olaparib Fails to Improve Survival in mCRPC
September 29th 2022Results from the phase 3 KEYLYNK-010 study showed that treatment with pembrolizumab and olaparib did not result in a statistically significant improvement in survival despite yielding higher responses compared with novel hormonal agents in patients with previously treated prostate cancer.